Retour
Prix Starpharma Holdings Limited (SPHRY)
Graphique du cours de l'action SPHRY
SPHRY Gagner
Starpharma Holdings Limited
$2.3
0%
$0
À la fermeture : Jan 26, 16:00:00 GMT-5
$2.3
0%
$0
Post-Marché: Jan 26, 20:00:00 GMT-5
Earnings FAQ
Comment le bénéfice par action récent de SPHRY se compare-t-il aux attentes ?
Comment les revenus de Starpharma Holdings Limited SPHRY se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Starpharma Holdings Limited ?
Quel est le score de qualité des bénéfices pour Starpharma Holdings Limited ?
Quand Starpharma Holdings Limited publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Starpharma Holdings Limited ?
Starpharma Holdings Limited a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$2.3
Prix d'ouverture
$2.3
Plage de la journée
$2.3 - $2.3
Plage de 52 semaines
$0.47 - $2.86
Volume
1.1K
Volume moyen
946
BPA (TTM)
-0.16
Rendement en dividend
--
Capitalisation boursière
$96.5M
Qu’est-ce que Starpharma Holdings Ltd. ?
Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. The firm's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The firm's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. The company also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The firm has applied its DEP technology to the innovative area of antibody-drug conjugates.
Fonctionnalités
Stratégies de trading
Ressources
© 2025 Finture Development Limited. All rights reserved